Distinct Pharmacokinetics, Tissue Distribution and CNS Penetration of ABI-009 (nab-Sirolimus)

Home Distinct Pharmacokinetics, Tissue Distribution and CNS Penetration of ABI-009 (nab-Sirolimus)

Distinct Pharmacokinetics, Tissue Distribution and CNS Penetration of ABI-009 (nab-Sirolimus)

/ Publications

Share the Post

About the Author

Related Posts

A phase 2 trial with ABI-009 (nab-sirolimus) as single-agent and combinations in recurrent high-grade glioma (rHGG) and in newly diagnosed glioblastoma (ndGBM)
nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors
UPDATE – Aadi Bioscience Presents Two Abstracts on FYARRO (nab-Sirolimus) at the Annual Meeting of the Connective Tissue Oncology Society (CTOS)
Read More
Neil Desai, PhD
Aadi Bioscience Appoints Scott Giacobello as Chief Financial Officer
Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)
ABI-009, nab-Sirolimus, an mTOR Inhibitor with High Lung Accumulation in Preclinical Models: Initial Results from an Ongoing Phase I/II Safety and Preliminary Efficacy Study in Severe PAH
Aadi Bioscience Receives Breakthrough Therapy Designation for ABI-009 in PEComa Indication

Comments

Comments are closed.